The earnings call highlighted strong revenue and volume growth, particularly in the oncology segment with Signatera. The company raised its financial guidance significantly and introduced promising new products and AI initiatives. However, flat operating expenses and the exit from the paternity business were noted as areas of concern. Nevertheless, the positive aspects, including strong market performance and strategic innovations, dominate the outlook.

Company Guidance -

Q3 2025

During Natera's 2025 Second Quarter Financial Results Conference Call, the company announced impressive metrics and updates across its operations. Natera reported $547 million in revenue, marking a 32% year-over-year increase, with an even higher growth of 34% excluding revenue true-ups. A notable achievement was the processing of 189,000 oncology tests, translating to a sequential growth of nearly 20,000 units, setting a new company milestone. Gross margin improved to 63.4%, up from approximately 59% the previous year. The company raised its annual revenue guidance to a range of $2.02 billion to $2.1 billion and adjusted its gross margin outlook to between 61% and 64%. Natera also highlighted its launch of Fetal Focus and ongoing advancements in organ health and oncology, such as the PROCEED trial for early cancer detection expected to read out later this fall. Operationally, they maintained their focus on cost management and efficiency, driven by AI initiatives, while keeping operating expenses flat despite revenue growth.

Revenue Growth

Natera achieved $547 million in revenue for Q2 2025, representing a 32% growth over Q2 2024, and 34% growth year-on-year excluding revenue true-ups.

Signatera Performance

Processed 189,000 oncology tests, with nearly 20,000 units of growth compared to Q1 2025, marking a new milestone with strong growth in new patient starts, doubling the previous quarterly record.

Gross Margin Improvement

Gross margin increased to 63.4% compared to approximately 59% in the previous year, with consistent sequential margins due to strong ASPs.

Raised Financial Guidance

Revenue guidance for 2025 increased by $80 million to a range of $2.02 billion to $2.1 billion, with gross margin guidance raised to 61% to 64%.

Launch of Fetal Focus NIPT

Natera launched a new NIPT for inherited conditions that demonstrated 91% sensitivity in detecting affected pregnancies in early clinical trials.

Organ Health and Oncology Data

Positive data from the PEDAL study in organ health and several studies in oncology, including breast and GI cancers, showcasing potential for improved patient management.

AI Initiatives and New Algorithms

Introduction of AI-based discovery and care platforms, including NeoPredict and NeoSelect algorithms, enhancing capabilities for predicting immune therapy responses and identifying neoantigens.

Natera (NTRA) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

NTRA Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.38 / -	-0.26	―	―	―
Aug 07, 2025	2025 (Q2)	-0.61 / -0.74	-0.3	-146.67% (-0.44)
May 08, 2025	2025 (Q1)	-0.64 / -0.50	-0.56	10.71% (+0.06)
Feb 27, 2025	2024 (Q4)	-0.38 / -0.41	-0.65	36.92% (+0.24)
Nov 12, 2024	2024 (Q3)	-0.57 / -0.26	-0.95	72.63% (+0.69)
Aug 08, 2024	2024 (Q2)	-0.69 / -0.30	-0.97	69.07% (+0.67)
May 09, 2024	2024 (Q1)	-0.70 / -0.56	-1.23	54.47% (+0.67)
Feb 28, 2024	2023 (Q4)	-0.77 / -0.65	-1.37	52.55% (+0.72)
Nov 08, 2023	2023 (Q3)	-0.96 / -0.95	-1.25	24.00% (+0.30)
Aug 03, 2023	2023 (Q2)	-1.09 / -0.97	-1.5	35.33% (+0.53)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

NTRA Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$141.08	$151.95	+7.70%
May 08, 2025	$162.57	$151.95	-6.53%
Feb 27, 2025	$156.61	$155.59	-0.65%
Nov 12, 2024	$135.12	$160.97	+19.13%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Natera (NTRA) report earnings?

Natera (NTRA) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).

What is Natera (NTRA) earnings time?

Natera (NTRA) earnings time is at Nov 05, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is NTRA EPS forecast?

NTRA EPS forecast for the fiscal quarter 2025 (Q3) is -0.38.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing